Protara Therapeutics, Inc., a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, announced that management will present at two upcoming virtual investor conferences:
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two upcoming virtual investor conferences:
- Guggenheim Healthcare Talks 2021 Oncology Days on Thursday, February 11, 2021 at 9:30am ET
- Cowen 41st Annual Health Care Conference on Wednesday, March 3, 2021 at 1:20pm ET
A webcast of the fireside chat presentations can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcasts will be archived on the Company’s website for 90 days following the presentations.
About Protara Therapeutics, Inc.
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
Company Contact:
Justine O’Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
